Pantano, Lorena
Agyapong, George
Shen, Yang
Zhuo, Zhu
Fernandez-Albert, Francesc
Rust, Werner
Knebel, Dagmar
Hill, Jon
Boustany-Kari, Carine M.
Doerner, Julia F.
Rippmann, Jörg F.
Chung, Raymond T.
Ho Sui, Shannan J.
Simon, Eric
Corey, Kathleen E.
Funding for this research was provided by:
Boehringer Ingelheim
Article History
Received: 23 April 2021
Accepted: 5 August 2021
First Online: 10 September 2021
Competing interests
: KEC serves on the scientific advisory board for Novo Nordisk and Bristol Myers Squibb (BMS) and has received grant funding (to institution) from Boehringer Ingelheim, BMS and Novartis. RTC has received grant funding (to institution) from Boehringer Ingelheim, BMS, Abbvie, Gilead, Merck, Roche, and Janssen. SHS has received grant funding (to institution) from Boehringer Ingelheim and AstraZeneca. LP, ZZ, and GA do not have any competeting interests. YS, FFA, WR, DK, JH, CMBK, JFD, JFR, and ES are employees of Boehringer Ingelheim and do not have any further competeting interests.